Previous 10 | Next 10 |
The FDA has accepted for review an application from ANI Pharmaceuticals ( ANIP -2.9% ) seeking approval to re-commercialize Purified Cortrophin Gel (repository corticotropin injection USP) 80U/mL. The agency's action date is July 23. More news on: ANI Pharmaceuticals, Inc., Mallinckrod...
BAUDETTE, Minn. , April 13, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that the U.S. Food & Drug Administration ("FDA") has accepted its supplemental new drug application ("sNDA") for Purified Cortrophin® Gel (Repository Cortic...
ANI Pharmaceuticals ( ANIP +1.6% PM) launched their 49th commercial generic drug - Omega-3-Acid Ethyl Esters Capsules, 1 gram. More news on: ANI Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
BAUDETTE, Minn. , April 2, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Omega-3-Acid Ethyl Esters Capsules USP, 1 gram. The current annual U.S. market for this product is approximately $110 million , according to IQVIA/IMS...
BAUDETTE, Minn. , March 26, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Polyethylene Glycol 3350, 17g/Packet (PEG-3350). The current annual market for this over the counter (OTC) product is approximately $21 million , according...
ANI Pharmaceuticals ( ANIP +13.1% ) has filed a marketing application with the FDA seeking approval to reintroduce Purified Cortrophin Gel (repository corticotropin injection USP) (80 U/mL) into the U.S. market aimed at taking market share from Mallinckrodt's ( MNK +0.6% ) top seller A...
BAUDETTE, Minn. , March 24, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP), an emerging leader in the specialty pharmaceutical industry, today announced that it has submitted a prior approval supplement (PAS) to the Endocrinology Division at the FDA for re-comm...
Image source: The Motley Fool. ANI Pharmaceuticals Inc (NASDAQ: ANIP) Q4 2019 Earnings Call Feb 27, 2020 , 10:30 a.m. ET Operator Continue reading
ANI Pharmaceuticals, Inc. (ANIP) Q4 2019 Earnings Conference Call February 27, 2020, 10:30 AM ET Company Participants Arthur Przybyl - CEO Stephen Carey - CFO Conference Call Participants Dana Flanders - Guggenheim Elliot Wilbur - Raymond James Brandon Folkes - Cantor Fit...
ANI Pharmaceuticals (NASDAQ: ANIP ): Q4 Non-GAAP EPS of $1.08 misses by $0.10 ; GAAP EPS of -$0.41 misses by $0.56 . More news on: ANI Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
ANI Pharmaceuticals Inc. Company Name:
ANIP Stock Symbol:
NASDAQ Market:
ANI Pharmaceuticals Inc. Website:
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched L-Glutamine Oral Po...
2024-07-09 17:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) and launched Naproxen Delayed-Release Tablets, USP....